The Rationale-301 study (phase III) demonstrated non-inferior median overall survival for tislelizumab (PD-1-inhibitor) versus sorafenib in patients with previously untreated unresectable HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.